The first large-scale trial is the Prevention of Ischaemic Complication (EPIC) study, which compares the use of abciximab (borus followed by 12-hour infusion) in 2100 high-risk patients undergoing PTCA1. Compared to placebo, abciximab resulted in a 35% reduction in 30-day primary end-points of death, acute MI or urgent reintervention. An increase of bleeding complications has been found in this study using concomitant standard dosage of heparin, but the risk could be reduced by appropriate heparin dosage adjustment. The benefit of abciximab appeared to last up to 3 years, with a 13% long-term reduction in these composite endpoints.
CHU-PAK LAU, WAI-HONG CHEN, Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndrome Journal of the Hong Kong College of Cardiology 1999;7(1):1-2 https://doi.org/10.55503/2790-6744.1477
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.